基石藥業(02616.HK):GEMSTONE-302研究達到統計學顯著性
基石藥業-B(02616.HK)公布,在2020年歐洲腫瘤內科學會亞洲年會線上年會上以口頭報告形式首次公佈了GEMSTONE-302研究詳細結果。結果顯示舒格利單抗聯合化療較安慰劑聯合化療,作為晚期非小細胞肺癌(「NSCLC」)一線治療,顯著延長了研究者評估的無進展生存期(「PFS」)。結果達到統計學顯著性,且有臨床意義。舒格利單抗聯合化療的安全性良好,未發現新的安全性信號。
GEMSTONE-302 是全球首個抗 PD-L1 單抗聯合化療作為一線治療在 IV 期鱗狀和非鱗狀NSCLC患者中的隨機雙盲III期臨床試驗。該研究旨在評估舒格利單抗聯合化療對比安慰聯合化療,在未經一線治療的、IV期NSCLC患者中的有效性和安全性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.